Skip to content

Study · In vitro (cells) · rat · 2006

1 result

Characterization of ghrelin receptor activity in a rat pituitary cell line RC-4B/C.

Falls HD, Dayton BD, Fry DG, Ogiela CA, Schaefer VG, Brodjian S, Reilly RM, Collins CA, Kaszubska W

Journal of molecular endocrinology1 Aug 2006Cited by 20 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat pituitary RC-4B/C cells, hexarelin caused a dose-dependent increase in intracellular calcium with an EC50 of 1.7 nM.

    In plain wordsIn rat pituitary cells in the lab, hexarelin raised calcium inside the cells in a dose-dependent way.

    Peptide
    Hexarelin
    Outcome
    IncreaseIntracellular Ca2+ mobilization (EC50)
    Study

    ratn: not reported in source

    RC-4B/C rat pituitary adenoma cell line
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · added to cellsAs given in this study (rat).

    Measurements

    EC50
    1.7 nM
    hexarelin, Ca(2+) mobilization in RC-4B/C cells

    Source sentences

    Summary
    In a Ca(2+)mobilization assay, RC-4B/C cells demonstrate a dose-dependent increase in intracellular [Ca(2+)] on stimulation with rat ghrelin and a related peptide agonist, hexarelin (EC(50), 1.0 nM and 1.7 nM respectively), but are unresponsive to treatment with inactive des-octanoyl rat ghrelin.
    1 context sentence
    Summary · context
    We show here that a cell line derived from a rat anterior pituitary adenoma, RC-4B/C, expresses endogenous GHS-R as judged by reverse transcriptase-PCR.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.